Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques

Andrew J. Carter, Karen Hicks, Alan W. Heldman, Jon R Resar, John R. Laird, Vicki J. Coombs, Jeffrey A Brinker, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

A new microsample coagulation analyzer (Hemochron® Jr.) has recently been developed which performs a modified activated clotting time (ACT +) and an aPTT by using different reagents. The Hemochron® Jr. measures the clotting time of a 5-microliter whole-blood sample by an optical detector and extrapolates the results to the activated clotting time (ACT+) or the plasmaactivated partial thromboplastin time by using a validated regression analysis. We compared 124 simultaneous ACT+ and Hemochron® ACTs, and 53 paired Hemochron® Jr. aPTTs and hospital laboratory aPTTs, in 44 patients during coronary intervention. The Hemochron® Jr. aPTT closely correlated with the lab aPTT (r = .79, P <.0001), and the test results were available much more rapidly than the lab aPTT (3.5 ± 1.1 vs. 56.3 ± 25.5 min, P=0.0029). A comparison of duplicate ACT+ measurements did not identify a significant difference in the means (292 ± 115 sec vs. 293 ± 112 sec, P=0.72). The ACT+ closely correlated with the Hemochron® ACTs (r = .85, P <.0001). At baseline, the mean ACT+ (175 ± 43 sec) exceeded the Hemochron® ACT (144 ± 36 sec) by 22% (P <.001). After heparin administration, the mean ACT+ (378 ± 74 sec) exceeded the Hemochron® ACT (332 ± 65) by 12% (P <.001). The Hemochron® Jr. provides a fast and reproducible methodology for measuring ACT and aPTT, using a small blood volume. Further studies are required to determine the optimal anticoagulation range when using the Hemochron® Jr. during or after interventional procedures.

Original languageEnglish (US)
Pages (from-to)97-102
Number of pages6
JournalCatheterization and Cardiovascular Diagnosis
Volume39
Issue number1
DOIs
StatePublished - Sep 1996

Fingerprint

Hospital Laboratories
Partial Thromboplastin Time
Blood Volume
Heparin
Regression Analysis

Keywords

  • anticoagulation
  • heparin
  • PTCA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques. / Carter, Andrew J.; Hicks, Karen; Heldman, Alan W.; Resar, Jon R; Laird, John R.; Coombs, Vicki J.; Brinker, Jeffrey A; Blumenthal, Roger S.

In: Catheterization and Cardiovascular Diagnosis, Vol. 39, No. 1, 09.1996, p. 97-102.

Research output: Contribution to journalArticle

@article{f1bcfdc8f71541faa70af2ec0b0bf261,
title = "Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques",
abstract = "A new microsample coagulation analyzer (Hemochron{\circledR} Jr.) has recently been developed which performs a modified activated clotting time (ACT +) and an aPTT by using different reagents. The Hemochron{\circledR} Jr. measures the clotting time of a 5-microliter whole-blood sample by an optical detector and extrapolates the results to the activated clotting time (ACT+) or the plasmaactivated partial thromboplastin time by using a validated regression analysis. We compared 124 simultaneous ACT+ and Hemochron{\circledR} ACTs, and 53 paired Hemochron{\circledR} Jr. aPTTs and hospital laboratory aPTTs, in 44 patients during coronary intervention. The Hemochron{\circledR} Jr. aPTT closely correlated with the lab aPTT (r = .79, P <.0001), and the test results were available much more rapidly than the lab aPTT (3.5 ± 1.1 vs. 56.3 ± 25.5 min, P=0.0029). A comparison of duplicate ACT+ measurements did not identify a significant difference in the means (292 ± 115 sec vs. 293 ± 112 sec, P=0.72). The ACT+ closely correlated with the Hemochron{\circledR} ACTs (r = .85, P <.0001). At baseline, the mean ACT+ (175 ± 43 sec) exceeded the Hemochron{\circledR} ACT (144 ± 36 sec) by 22{\%} (P <.001). After heparin administration, the mean ACT+ (378 ± 74 sec) exceeded the Hemochron{\circledR} ACT (332 ± 65) by 12{\%} (P <.001). The Hemochron{\circledR} Jr. provides a fast and reproducible methodology for measuring ACT and aPTT, using a small blood volume. Further studies are required to determine the optimal anticoagulation range when using the Hemochron{\circledR} Jr. during or after interventional procedures.",
keywords = "anticoagulation, heparin, PTCA",
author = "Carter, {Andrew J.} and Karen Hicks and Heldman, {Alan W.} and Resar, {Jon R} and Laird, {John R.} and Coombs, {Vicki J.} and Brinker, {Jeffrey A} and Blumenthal, {Roger S}",
year = "1996",
month = "9",
doi = "10.1002/(SICI)1097-0304(199609)39:1<97::AID-CCD22>3.0.CO;2-K",
language = "English (US)",
volume = "39",
pages = "97--102",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques

AU - Carter, Andrew J.

AU - Hicks, Karen

AU - Heldman, Alan W.

AU - Resar, Jon R

AU - Laird, John R.

AU - Coombs, Vicki J.

AU - Brinker, Jeffrey A

AU - Blumenthal, Roger S

PY - 1996/9

Y1 - 1996/9

N2 - A new microsample coagulation analyzer (Hemochron® Jr.) has recently been developed which performs a modified activated clotting time (ACT +) and an aPTT by using different reagents. The Hemochron® Jr. measures the clotting time of a 5-microliter whole-blood sample by an optical detector and extrapolates the results to the activated clotting time (ACT+) or the plasmaactivated partial thromboplastin time by using a validated regression analysis. We compared 124 simultaneous ACT+ and Hemochron® ACTs, and 53 paired Hemochron® Jr. aPTTs and hospital laboratory aPTTs, in 44 patients during coronary intervention. The Hemochron® Jr. aPTT closely correlated with the lab aPTT (r = .79, P <.0001), and the test results were available much more rapidly than the lab aPTT (3.5 ± 1.1 vs. 56.3 ± 25.5 min, P=0.0029). A comparison of duplicate ACT+ measurements did not identify a significant difference in the means (292 ± 115 sec vs. 293 ± 112 sec, P=0.72). The ACT+ closely correlated with the Hemochron® ACTs (r = .85, P <.0001). At baseline, the mean ACT+ (175 ± 43 sec) exceeded the Hemochron® ACT (144 ± 36 sec) by 22% (P <.001). After heparin administration, the mean ACT+ (378 ± 74 sec) exceeded the Hemochron® ACT (332 ± 65) by 12% (P <.001). The Hemochron® Jr. provides a fast and reproducible methodology for measuring ACT and aPTT, using a small blood volume. Further studies are required to determine the optimal anticoagulation range when using the Hemochron® Jr. during or after interventional procedures.

AB - A new microsample coagulation analyzer (Hemochron® Jr.) has recently been developed which performs a modified activated clotting time (ACT +) and an aPTT by using different reagents. The Hemochron® Jr. measures the clotting time of a 5-microliter whole-blood sample by an optical detector and extrapolates the results to the activated clotting time (ACT+) or the plasmaactivated partial thromboplastin time by using a validated regression analysis. We compared 124 simultaneous ACT+ and Hemochron® ACTs, and 53 paired Hemochron® Jr. aPTTs and hospital laboratory aPTTs, in 44 patients during coronary intervention. The Hemochron® Jr. aPTT closely correlated with the lab aPTT (r = .79, P <.0001), and the test results were available much more rapidly than the lab aPTT (3.5 ± 1.1 vs. 56.3 ± 25.5 min, P=0.0029). A comparison of duplicate ACT+ measurements did not identify a significant difference in the means (292 ± 115 sec vs. 293 ± 112 sec, P=0.72). The ACT+ closely correlated with the Hemochron® ACTs (r = .85, P <.0001). At baseline, the mean ACT+ (175 ± 43 sec) exceeded the Hemochron® ACT (144 ± 36 sec) by 22% (P <.001). After heparin administration, the mean ACT+ (378 ± 74 sec) exceeded the Hemochron® ACT (332 ± 65) by 12% (P <.001). The Hemochron® Jr. provides a fast and reproducible methodology for measuring ACT and aPTT, using a small blood volume. Further studies are required to determine the optimal anticoagulation range when using the Hemochron® Jr. during or after interventional procedures.

KW - anticoagulation

KW - heparin

KW - PTCA

UR - http://www.scopus.com/inward/record.url?scp=0029789074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029789074&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0304(199609)39:1<97::AID-CCD22>3.0.CO;2-K

DO - 10.1002/(SICI)1097-0304(199609)39:1<97::AID-CCD22>3.0.CO;2-K

M3 - Article

VL - 39

SP - 97

EP - 102

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -